Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$21.24 USD
+0.08 (0.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.24 USD
+0.08 (0.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Zacks News
Catalyst (CPRX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Catalyst (CPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Catalyst Pharmaceuticals (CPRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Catalyst Pharmaceutical (CPRX) and Lyell Immunopharma (LYEL) have performed compared to their sector so far this year.
Spectrum Pharmaceuticals (SPPI) Gets Nod for Rolvedon Injection
by Zacks Equity Research
Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia.
Here's How Much You'd Have If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Zacks.com featured highlights include Tsakos Energy, AVEO Pharmaceuticals and Catalyst Pharmaceuticals
by Zacks Equity Research
Tsakos Energy, AVEO Pharmaceuticals and Catalyst Pharmaceuticals have been highlighted in this Screen of The Week article.
Buy These 3 Top Breakout Stocks Now for Superb Returns
by Tirthankar Chakraborty
Tsakos Energy Navigation (TNP), AVEO Pharmaceuticals (AVEO) and Catalyst Pharmaceuticals (CPRX) have been selected as the breakout stocks for today.
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma
by Zacks Equity Research
Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.
Catalyst (CPRX) Up 13.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Pharmaceutical (CPRX) Just Reclaimed the 20-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds
by Zacks Equity Research
Ironwood (IRWD) reports positive top-line data from a late-stage study evaluating Linzess (linaclotide) for functional constipation in pediatric patients aged six to 17 years.
Immunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer Candidate
by Zacks Equity Research
Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.
Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based Booster
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) complete submission of conditional marketing authorization to the European Medicines Agency for Omicron BA.4/BA.5-adapted bivalent vaccine.
3 Reasons Why Catalyst (CPRX) Is a Great Growth Stock
by Zacks Equity Research
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
Here's Why Catalyst Pharmaceutical (CPRX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Has Aerie Pharmaceuticals (AERI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aerie Pharmaceuticals (AERI) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
If You Invested $1000 in Catalyst Pharmaceutical 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up
by Zacks Equity Research
Catalyst (CPRX) beat earnings and sales estimate in second-quarter 2022 earnings. Consequently, the stock surges.
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More
by Kinjel Shah
Let us look at four drug and biotech companies, EXEL, BHC, CPRX and AXSM, which are gearing up for their earnings release.
Catalyst Pharmaceuticals (CPRX) Rallies 43% YTD: Here's Why
by Zacks Equity Research
Catalyst's (CPRX) price rallies on the back of the robust performance of its lead drug, Firdapse, approved for treating LEMS in adults. The company is also trying to launch Firdapse in the international markets.
Catalyst (CPRX) Stock Jumps 10%: Will It Continue to Soar?
by Zacks Equity Research
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug
by Zacks Equity Research
Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.
Catalyst (CPRX) Up 6.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
by Zacks Equity Research
Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.
Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?